HOME > LATEST
LATEST
-
REGULATORY MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
February 13, 2026
-
REGULATORY MHLW Orders Label Revisions for Sulfite-Containing Medical Products
February 13, 2026
-
BUSINESS Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
-
BUSINESS Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
-
BUSINESS FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
-
BUSINESS Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
-
REGULATORY PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
-
REGULATORY PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
-
REGULATORY Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
-
BUSINESS MFN Policy Could Affect Business Outside US: Kyowa Kirin CEO
February 12, 2026
-
BUSINESS Kyowa Kirin Aims to Raise Core Margin to 30% on Late-Stage Launches
February 12, 2026
-
BUSINESS Chugai Exercises Option to Develop Multi-Payload ADCs with Araris
February 12, 2026
-
BUSINESS Astellas Settles US Myrbetriq Patent Row with Lupin, Zydus
February 12, 2026
-
BUSINESS Rohto Invests More in Osaka University Spinout Raymei
February 12, 2026
-
BUSINESS Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
February 12, 2026
-
BUSINESS J&J Files Tecvayli/Darzquro Combo for MM in Japan
February 12, 2026
-
BUSINESS Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
-
BUSINESS Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
-
BUSINESS Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
-
BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
